RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 1999; 82(02): 165-174
DOI: 10.1055/s-0037-1615780
DOI: 10.1055/s-0037-1615780
Research Article
Biochemistry and Physiology of Blood Coagulation
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
09. Dezember 2017 (online)
Introduction
The biochemical investigation of a biological process can be divided into three segments. The first is the development of an inventory of the components involved in the process, the second is the establishment of the connectivity between components, and the third is the establishment of the dynamics of the processes as they occur in the living organism.
-
References
- 1 Schmidt A. Neue Untersuchungen ueber die Fasserstoffesgerinnung. Pflueger’s Arch.f.ges.Physiol. 1872; 6: 413-538.
- 2 Morawitz P. Die Chemie der Blutgerrinnung. Ergebn Physiol. 1905; 4: 307-423.
- 3 Patek AJ, Taylor FHL. Hemophilia II: some properties of a substance obtained from normal plasma effective in accelerating the clotting of hemophilic blood. J Clin Invest. 1937; 113-124.
- 4 Brinkhous KM. Clotting defect in hemophilia: deficiency in a plasma factor required for platelet utilization. Proc Soc Exp Biol Med. 1947; 66: 117-120.
- 5 Aggeler PM, White SG, Glendenning MB. Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc Soc Exp Bio Med. 1952; 79: 692-694.
- 6 Schulman ISCH. Hemorrhagic disease in an infant due to deficiency of a previously undescribed clotting factor. Blood 1952; 7: 794-807.
- 7 Biggs R, Douglas AS, MacFarlane RG. et al. Christmas disease: a condition previously mistaken for hemophilia. Br Med J. 1952; 2: 1378-1382.
- 8 Bachmann F, Duckert F, Koller K. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh. 1999; 2: 24-38.
- 9 Alexander B, Goldstein RA, Landweher G. et al. Congenital SPCA deficiency: a hither to unrecognized coagulation defect with hemorrhage rectified by serm and serum fractions. J Clin Invest. 1951; 30: 596-608.
- 10 Soulier JP, Wartell O, Menache D. Caracteres differentiels des facteurs hageman et P.T.A.; role due contact dans la phase initiate de la coagulation. Rev Franc Etudes Clin Biol. 1958; 3: 363
- 11 Botti RE, Ratnoff OD. The clot-promoting effect of soaps of long-chain saturated fatty acids. J.Clin.Invest. 1963; 42: 1569-1577.
- 12 Owren PA. Parahaemophilia. Haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947; 1: 446-448.
- 13 Wright IS. The nomenclature of blood clotting factors. Thromb Diath Haemost. 1962; 7: 381-388.
- 14 Warner ED, Brinkhous KM, Smith HP. A quantitative study of blood clotting. Am J Physiol. 1936; 114: 667-675.
- 15 Quick AJ. On the Constitution of Prothrombin. Am J Physiol. 1999; 140: 212-220.
- 16 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a single one-stage antihemophilic factor assay procedure. J Lab Clin Med. 1953; 41: 7637-7647.
- 17 Ratnoff OD, Colpy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest. 1955; 34: 602-613.
- 18 Jacobsen SFM. Some data on two purified kininogens from human plasma. Br.J.Pharmacol. 1967; 29: 25
- 19 Mandle Jr R, Coleman RW, Kaplan AP. Identification of prekallikrein and high molecular weight kininogen complex in plasma. Proc Natl Acad Sci USA. 1976; F3: 4179-4183.
- 20 Duckert F, Jung SH, Schmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh. 1961; 5: 179-186.
- 21 Howell WH. The role of antithrombin and thromboplastin (thromboplastic substance) in the coagulation of blood. Am J Physiol. 1911; 29: 187-209.
- 22 Broze Jr. GJ, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA. 1987; 84: 1886-1890.
- 23 Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modification of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA. 1974; 71: 2730-2733.
- 24 Kisiel W. Human plasma protein C. Isolation, characterization and mechanism of activation by alpha-thrombin. J Clin Invest. 1979; 64: 761-769.
- 25 DiScipio RG, Davie EW. Characterization of protein S, a gamma-carboxy-glutamic acid containing protein from bovine and human plasma. Biochem. 1979; 18: 899-904.
- 26 Broze GJ, Miletich J. Human Protein Z. J Clin Invest. 1984; 73: 933.
- 27 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin catalyzed activation of protein C. Proc Natl Acad Sci USA. 1981; 78: 2249-2252.
- 28 MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498-499.
- 29 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312.
- 30 Osterud B, Rapaport SI. Activation of Factor IX by the reaction product of tissue Factor and Factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci. 1977; 74: 5260-5260.
- 31 Gailani D, Broze Jr. GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
- 32 Ware AG, Seegers WH. Two Stage Procedure for the Quantitative Determination of Prothrombin Concentration. Am J Clin Path. 1949; 19: 471-482.
- 33 Seegers WH. Activation of Purified Prothrombin. Proc Soc Exptl Biol Med. 1949; 72: 677-680.
- 34 Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood and cell populations. J Biol Chem. 1985; 260: 2119-2124.
- 35 Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem. 1988; 263: 16467-16470.
- 36 Weiss HJ, Turitto VT, Baumgartner HR. The role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium:Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest. 1986; 78: 1072
- 37 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone Jr. MA. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984; 160: 618-623.
- 38 Mann K, Nesheim M, Church W, Haley P, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
- 39 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
- 40 Lawson JH, Butenas S, Mann KG. The evaluation of complex-dependent alterations in human factor VIIa. J Biol Chem. 1992; 267: 4834-4843.
- 41 Broze Jr. GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry. 1990; 29: 7539-7546.
- 42 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989; 264: 4743-4746.
- 43 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994; 269: 31869-31880.
- 44 Fay PJ, Smudzin TM. Characterization of the Interaction of the A2 Subunit and AI/A3-C1-C2 Dimer in Human Factor VIII. J Biol Chem. 1992; 267: 13246-13250.
- 45 Rosenberg RD, Damus PS. The Purification and Action of Human Antithrombin-Heparin Cofactor. J Biol Chem. 1973; 248: 6490-6505.
- 46 Marcum JA, Rosenberg RD. Anticoagulantly active heparinlike molecules from vascular tissue. Biochemistry. 1984; 23: 1730-1730.
- 47 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin: 1. an empirical study. J Biol Chem. 1994; 269 (37) 23357-23366.
- 48 van ‘t Veer C Golden NJ, Kalafatis M, Mann KG. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation: synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem. 1997; 272: 7983-7994.
- 49 van ‘t Veer C Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor II. J Biol Chem. 1997; 272: 4367-4377.
- 50 van ‘tVeer C Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor-initiated prothrombin activation as a result of the Arg506-Gln Mutation in factor VLeiden . J Biol Chem. 1997; 272: 20721-20729.
- 51 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin: 2. a mathematical simulation. J Biol Chem. 1994; 269 (37) 23367-23373.
- 52 Shafi T, Jeha JM, Black L, Al Douri M. Severe acquired haemophilia A treated with recombinant factor VIIa. Br J Haematol. 1997; 98: 910-912.
- 53 Rand MD, Lock JB. van ‘t Veer C et al. Blood clotting in minimally altered whole blood. Blood 1997; 88: 3432-3445.
- 54 Cawthern KM, van ‘t Veer C Locke JB, DiLorenzo ME, Branda RF, Mann KG. Blood Coagulation in Hemophilia A and Hemophilia C. Blood 1998; 91: 4581-4592